A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Savolitinib (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 22 May 2019 Planned End Date changed from 30 Sep 2019 to 31 Jan 2022.
- 22 May 2019 Planned primary completion date changed from 30 Sep 2019 to 31 Jan 2022.
- 22 May 2019 Status changed from not yet recruiting to recruiting.